An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?

European Journal of Cancer Part A

Volumn 32, Issue 11, 1996, Pages 1949-1956

  Chapman, J W ^a,b   Murray, D ^a,c   McCready, D R ^a,b   Hanna, W ^a,b   Kahn, H J ^a,b   Lickley, H L A ^a,b   Trudeau, M E ^a,b   Mobbs, B G ^a,b   Sawka, C A ^a,d   Fish, E B ^a,b   Pritchard, K I ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Breast cancer; Cell cycle modelling; Prognostic factors; Statistical analysis

Indexed keywords

TUMOR MARKER;

ARTICLE; BREAST CANCER; CELL CYCLE; FEMALE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; STATISTICS;

EID: 0030272788     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00232-8     Document Type: Review

References (33)

1. 1. McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990, 82, 1006-1012.
2. 2. Kallioniemi O-P, Isola J, Kallioniemi A, et al. Genetic events underlying breast cancer progression analyzed by comparative genomic hybridization. Proc Am Assoc Cancer Res 1994, 35, 250 (Abstr. 1491).
3. 3. Techniques in Diagnostic Pathology: Diagnostic Flow Cytometiy. Edited by Coon JS, Weinstein RS. Williams and Wilkins, Baltimore, 1991, 115-146.
4. 4. Viehl P. Guidelines to Clinical Aspiration Biology: Flow Cytometry. Igaku-Shoin, New York, 1991, 21-57.
5. 5. Leslies KO, Howard P. Oncogenes and Antioncogenes in Human Breast Cancer. Pathology Annual 1992, Part 1. Edited by Rosen PP, Fechner RE. Appleton and Lange Norwalk, Connecticut, 1992, 321-342.
6. 6. Clark GM. Integrating prognostic factors. Breast Cancer Res Treat 1992, 22, 187-191.
7. 7. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86, 829-835.
8. 8. Hilsenbeck SG, Clark GM, McGuire WL. Why do so many prognostic factors fail to pan out? Breast Cancer Res Treat 1992, 22, 197-206.
9. 9. Sawka CA, Pritchard KI, Lickley HLA, et al. The Henrietta Banting Breast Centre Database: a model for clinical research utilizing a hospital-based inception cohort. J Clin Epidemiol 1995, 48, 779-786.
10. 10. Hanna W, McCready DR, Chapman JW, et al. The predictive value of ERICA in breast cancer recurrence: a univariate and multivariate analysis. Mod Pathol 1993, 6, 748-754.
11. 11. Hanna WM, Kahn HJ, Chapman JW. The correlation of Ki67 growth factor and ERICA in breast cancer. Mod Pathol 1992, 5, 220-223.
12. 12. Mobbs BG, Chapman JW, Sutherland DJA, et al. Evidence for bimodal distribution of breast carcinoma ER and PgR values quantitated by enzyme immunoassay. Eur J Cancer 1993, 29A, 1293-1297.
13. 13. Chapman JW, Mobbs BG, Hanna WM, et al The standardization of estrogen receptors. J Steroid Biochem Mol Biol 1993, 45, 367-373.
14. 14. Chapman JW, Mobbs BG, McCready DR, et al. Estrogen and progesterone receptor assay cut-points for primary breast cancer. J Steroid Biochem Mol Biol, in press.
15. 15. Chapman JW, Murray D, Trudeau ME, et al. Optimal DNA index in a flow cytometry investigation of node negative breast cancer. Proc Am Assoc Cancer Res 1995, 36, 210 (Abstr. 1249).
16. 16. Chapman JW, Trudeau ME, Pritchard KI, et al. A comparison of all subset cox and accelerated failure time models with Cox step-wise regression for node positive breast cancer. Breast Cancer Res Treat 1992, 22, 263-272.
17. 17. Gundersen HJG, Bendtsen TF, Korbo L, et al. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1989, 96, 379-394.
18. 18. Gundersen HJG, Bagger P, Bendtsen TF, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96, 857-881.
19. 19. LaRoye GJ, Panzarella T. Two techniques for measuring invasion in solid tumors. Evaluated in a retrospective study of 73 cases of breast carcinoma with 10-year follow-up. APMIS 1994, 102, 103-111.
20. 20. Cohen JL, Raam S, Gelman R. A blinded study of inter-and intra-laboratory variations in the performance of estrogen receptor (ER) assay. In Sarfaty GJ, Nash AR, Keightley DD. Estrogen Receptor Assays in Breast Cancer, Laboratory Discrepancies and Quality Assurance, New York, Masson Publishing, 1981, 43-56.
21. 21. Ryan ED, Clark AF, Mobbs BG, Ooi TC, Sutherland DJA, Tustanoff ER. Inter-laboratory quality control of estrogen and progesterone receptor assays in breast cancer tissue using lyophilised cytosols. Clin Biochem 1985, 18, 20-26.
22. 22. Cren H, Lechevrel C, Roussel G, Goussard J. Evolution of immunoreactivity of monoclonal antibodies H222 and/or D547 used in the detection of breast cancer estrogen receptors. Varying reactivity of receptor isoforms. J Steroid Biochem Mol Biol 1991, 39, 519-527.
23. 23. International Normalized Ratio: Laboratory Monitoring of Oral Anticoagulants. Organon Teknika Product Information, 1994.
24. 24. Box GEP, Cox DR. Analysis of Transformations. J R Stat Soc, Series B 1964, 26, 211-252.
25. 25. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330, 1260-1266.
26. 26. Ravdin PM, Clark GM. A practical application of neural network analysis for predicting outcome of individual breast cancer patients. Breast Cancer Res Treat 1992, 22, 285-293.
27. 27. Kendall MG, Stuart A. The Advanced Theory of Statistics. Volume I, 3rd edition. Hafner Publishing Company, New York, 1969, 48.
28. 28. Hedley DW, Clark GM, Cornelisse CJ, et al. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 1993, 14, 482-485.
29. 29. Godolphin W, Elwood JM, Spinelli JJ. Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer. A study of 583 patients. Int J Cancer 1981, 28, 677-683.
30. 30. Albain KS, Green S, LeBlanc M3 Rivkin S, O'Sullivan J, Osborne CK. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer database: a pilot study. Breast Cancer Res Treat 1992, 22, 273-284.
31. 31. Hastie T, Sleeper L, Tibshirani R. Flexible covariate effects in the proportional hazards model. Breast Cancer Res Treat 1992, 22, 241-250.
32. 32. Ciampi A, Chapman J, Hogg SA, Thiffault J. GENCOV: a Fortran program that generates randomly censored survival data with covariates. Comp Meth Prog Biomed 1989, 29, 51-57.
33. 33. Pritchard KI, Trudeau ME, Chapman JW, et al. Prognostic variables in node-negative breast cancer: an all subset analysis. Proc Am Soc Clin Oncol 1993, 12, 68 (Abstr. 73).